Pneumonia After Heart Surgery: Can AI Predict It?

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective observational study will collect data from adults undergoing cardiac or vascular surgery to develop personalized AI-based risk calculators for post-surgical pneumonia and for a 1-year composite cardiovascular and pulmonary outcome. It will apply machine learning methods to identify risk factors and predict pneumonia development, aiming to support clinical decision-making with individualized risk estimates. No experimental treatments will be used; data analysis will be performed on anonymized patient records in accordance with approved medical care standards. The study involves three centers in Tomsk, Russia, and does not include interventional protocols beyond standard care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years;
* Cardiac and/or vascular surgical intervention during the current hospitalization;
* Signed informed consent from the patient for the use of their anonymized data for scientific purposes.

Exclusion Criteria:

* Use of systemic antibacterial drugs within 30 days prior to the surgical intervention;
* Prescription of systemic antibacterial drugs during the hospitalization period for any indication other than hospital-acquired pneumonia;
* HIV infection.

Where it's running

• Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
  Tomsk, Russia Recruiting

Study contacts

• Principal investigator: Tatiana P. Kalashnikova, MD, PhD — Cardiology Research Institute of Tomsk NRMC
• Study coordinator: Alla A. Boshchenko, MD, PhD, DSc
• Email: bosh@cardio-tomsk.ru
• Phone: + 7 (3822)-909055

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predictors and Outcomes of Ventilated Hospital-Acquired Pneumonia

  This study looks at which factors predict outcomes for patients with ventilated hospital-acquired pneumonia to help guide care.

  Recruiting Assiut University · Asyut, Asyut Governorate · NCT07667582

• Using dexamethasone to treat severe hospital-acquired pneumonia in critically ill patients

  This study is testing if adding dexamethasone to standard treatment helps critically ill patients with severe hospital-acquired pneumonia feel better compared to those who only get standard treatment.

  Recruiting at 19 sites Phase 3 Nantes University Hospital · Amiens and 33 other locations · NCT06269900

• Using acyclovir to treat pneumonia in ventilated patients with herpes simplex virus

  This study is testing if giving acyclovir to ICU patients on ventilators who have pneumonia and herpes simplex virus can help them survive better than those who don't receive the medication.

  Recruiting at 28 sites Phase 3 Jena University Hospital · Freiburg im Breisgau, Baden-Wurttemberg and 27 other locations · NCT06134492

• Early treatment with targeted antibiotics for severe infections using rapid diagnostics

  This study is testing if giving targeted antibiotics right away, based on quick test results, can help hospitalized patients with severe infections caused by tough-to-treat bacteria feel better faster than standard care.

  Recruiting at 21 sites Phase 4 National University of Singapore · Vellore and 20 other locations · NCT05979545

• Learning about the safety and effectiveness of Zavicefta in Korea

  This study is trying to learn how safe and effective Zavicefta is for treating serious infections in both adults and kids in Korea after it has been released for use.

  Recruiting Pfizer · Seoul, Gangnam-gu · NCT05733104

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.